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Abstract
Background: In recent years, there is considerable evidence of a relationship between the sensorimotor disorder
restless legs syndrome (RLS) and pain disorders, including migraine and fibromyalgia. An association between
multi-site pain and RLS has been reported in adult women. In the current study, we explored the association
between musculoskeletal (MSK) pain and RLS in a large cohort of young adults.
Methods: Twenty two year olds (n = 1072), followed since birth of part of the Western Australian Pregnancy Cohort
(Raine) Study, provided data on MSK pain (duration, severity, frequency, number of pain sites). RLS was considered
present when 4 diagnostic criteria recommended by the International Restless Legs Syndrome Study Group were
met (urge to move, dysaesthesia, relief by movement, worsening symptoms during the evening/night) and participants
had these symptoms at least 5 times per month. Associations between MSK pain and RLS were analyzed by multivariable
logistic regression with bias-corrected bootstrapped confidence intervals, with final models adjusted for sex, psychological
distress and sleep quality.
Results: The prevalence of RLS was 3.0 % and MSK pain was reported by 37.4 % of the participants. In multivariable
logistic regression models, strong associations were found between RLS-diagnosis and long duration (three months or
more) of MSK pain (odds ratio 3.6, 95 % confidence interval 1.4–9.2) and reporting three or more pain sites (4.9, 1.6–14.6).
Conclusions: Different dimensions of MSK pain were associated with RLS in young adults, suggestive of shared
pathophysiological mechanisms. Overlap between these conditions requires more clinical and research attention.
Keywords: Musculoskeletal pain, Restless legs syndrome, Sleep disorders
Background
Restless legs syndrome (RLS) is a neurological disorder
that causes an irresistible urge to move the legs, often
accompanied by unpleasant sensations. The symptoms
typically begin or worsen during periods of rest or inactiv-
ity, are worse during evening or night and are partially or
totally relieved by movement [1]. Large epidemiologic
surveys on RLS report prevalence estimates of between
4–7 % in adults [2, 3] and 2–4 % in children and adoles-
cents [4–6]. In the absence of diagnosis and appropriate
management, consequences of RLS include sleep disrup-
tion, increased daytime drowsiness, cognitive problems
and reduced quality of life [2, 7]. Moreover, several studies
have found high rates of comorbid psychiatric disorders in
RLS [8–10] and associations between RLS and cardiovas-
cular disease [11–13].
In recent years, there has been emerging evidence of a
clinically relevant relationship between RLS and pain
disorders. Associations between RLS and multiple pain
problems have been identified, including migraine [14]
and fibromyalgia [15, 16]. A recent Swedish population-
based study among middle-aged women found a strong
relationship between RLS and multi-site pain, and this
association increased with both pain severity and the
number of pain sites [17]. The strength of the association
highlights the possibility of common causal pathways.
Current theories on RLS pathophysiology emphasize brain
iron deficiency leading to altered dopaminergic meta-
bolism, combined with a strong genetic background [18].
This functional dysregulation of dopaminergic circuitry
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has been suggested by Stehlik et al. [17] as a mechanism
in both RLS and chronic multi-site pain.
The aim of the current study was to explore the associ-
ation between RLS and musculoskeletal (MSK) pain in a
community-based sample of young adults, while control-
ling for important confounding variables as sleep quality
and negative emotional symptoms. This study will be
among the first investigating the association between
MSK pain and RLS within this age group. Based on the
previous literature, we hypothesized that the association
between RLS and MSK pain will be greater in individuals
with severe MSK pain and with multiple pain sites.
Methods
Study population
Cross-sectional data were obtained from the participants
of the Western Australian Pregnancy Cohort (Raine) Study
(www.rainestudy.org.au) at the age of 22. This long-term
project began as a pregnancy cohort in which 2,900
women attending antenatal clinics at a tertiary level obstet-
ric hospital in Perth, Western Australia were enrolled be-
tween 1989 and 1991. After birth, 2,868 children remained
with the study to form the Raine Study cohort. An analysis
at the year 17 follow-up showed that the Raine cohort had
high similarity to the Western Australian population on
demographic characteristics [19]. The year 22 follow-up
was conducted between March 2012 and July 2014. The
study sample consisted of all active members of the cohort
(n = 2,086 or 72.7 % of the original cohort of 2,868), that is
those who had previously provided consent to be contacted
for follow-up and were not deceased (n = 40), had not
withdrawn (n = 566), or otherwise been lost to follow-up
(n = 176) [20]. A comparison of the active participants with
census data collected in 2011 on all similarly aged young
adults in Western Australia showed that the sample re-
mains representative on a range of variables including edu-
cation level, employment status, income, marital status,
number of offspring, hours work and occupation. Around
the time of their 22nd birthday, participants were con-
tacted by telephone and had the details of this follow-up
explained. Those wishing to participate were mailed ques-
tionnaires, participant information and a consent form.
1,072 participants (51.4 % of active participants) provided
data for the variables used in this study. Ethics approval
was granted from the Human Research Ethics Committees
at the University of Western Australia (approval number =
RA/4/1/5202) and Curtin University (HR67/2013). The
study was conducted in accordance with the Declaration of
Helsinki and all participants provided informed consent.
Data collection
Musculoskeletal pain
Questions on MSK pain were based on the Orebro
Musculoskeletal Pain Questionnaire [21]. Presence of
MSK pain was assessed from 10 possible pain areas
(neck, upper back, lower back, left/right shoulder, left/right
arm, left/right leg and other) and four categories related to
the number of pain sites were created: 1) no pain, 2) one
pain site, 3) two pain sites and 4) three or more pain sites.
The duration of the pain problem was defined as either of
1) short duration (less than three months) or 2) long dur-
ation (three months or more). The average pain intensity
during the last week and last three months was assessed
with a 11-point numerical pain rating scale with answer
options ranging from ‘no pain’ to ‘pain as bad as it could
be’ and categorized as 1) no pain (0–1), 2) mild pain (2–4),
3) moderate pain (5–6) or 4) severe pain (7–10). Average
pain frequency during the last three months was also
assessed with a 11-point numerical pain rating scale with
answer options ranging from ‘never’ to ‘always’ and was
classified as 1) no pain (0–1), 2) low frequency (2–4), 3)
medium frequency (5–6) and 4) high frequency (7–10).
Restless legs syndrome
Based on the recommendations of the International Rest-
less Legs Syndrome Study Group (IRLSSG) [1], four
screening questions were used to assess the prevalence of
RLS-related symptoms: 1) strong urge to move the legs
when sitting or lying down, 2) accompanying dysaesthesia,
3) relief by movement and 4) worsening of symptoms
during the evening/night. Individuals who answered all
four questions positively and had symptoms at least 5
times per month were assigned a questionnaire-based
RLS-diagnosis [22, 23].
Sleep quality
The subjective sleep quality component of the Pittsburgh
Sleep Quality Index [24] was used as an indicator for sleep
quality and four categories of sleep quality were assigned:
1) very good, 2) fairly good, 3) fairly bad and 4) very bad.
Anxiety/depression/stress
Data for anxiety, depression and stress were obtained
using the shortened version of the Depression, Anxiety
and Stress Scale (DASS-21) [25]. Although originally
developed to measure psychological burden along the
separate axes of depression, stress and anxiety, the DASS-
21 total score can be used as a composite measure of
negative emotional symptoms [25] and was used in this
manner.
Smoking and body mass index (BMI)
Smoking status was assessed with a single question (‘Do
you currently smoke cigarettes/cigars?’) and participants
were classified accordingly as smokers or non-smokers.
Height and weight were measured and BMI was
calculated.
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Statistical analyses
Pearson’s Chi square test was applied to test differences
in RLS-diagnosis prevalence across sex and MSK pain
(presence of any pain, pain duration, pain severity, pain
frequency and number of pain areas). Trends within
distributions were tested by means of the Pearson’s Chi
square test for trend.
A multivariable logistic regression analysis was per-
formed with RLS-diagnosis as the dependent variable.
Odds ratios (OR) with bias-corrected bootstrapped 95 %
confidence intervals (CI) using 1000 replications were
calculated for each MSK pain variable separately and the
participants with no RLS-diagnosis were used as the ref-
erence group. Confounding variables were identified and
incorporated into the models. The covariates used in the
final regression models were sex, DASS-21 total score
and sleep quality. An additional univariable analysis was
performed for the separate pain regions. Since numbers
per pain region were low, multivariable analysis per pain
region was not performed.
All statistical analyses were performed with IBM-SPSS
version 22 software (Chicago, IL, USA). A p-value of <0.05
was considered statistically significant.
Results
The characteristics of the study sample, with the reference
group compared to the RLS-diagnosis group, are shown
in Table 1.
RLS prevalence
All four RLS-diagnosis criteria were met in 32 partici-
pants, giving a prevalence of 3.0 % (Table 2). The preva-
lence in females was almost twice as high as in males
(3.8 vs 2.0 %), but this difference did not reach statistical
significance (p = 0.096). The 95 % confidence interval
estimate for difference in prevalence between males and
females was 0 to 3.7 %. Subjects with RLS reported
significantly poorer sleep quality compared with the ref-
erence group (p for trend = 0.023; Table 1). Moreover,
the RLS-diagnosis group had significantly higher scores
on all MSK pain variables and higher DASS-21 scores.
No significant differences in smoking status and BMI
were found.
Prevalence of musculoskeletal pain
Current MSK pain was reported by 37.4 % of the study
sample (Table 1). A short duration of pain (less than
three months) was reported by 13.8 %, whereas pain of
long duration (three months or more) was found in
23.5 %. The mean pain intensity score during the last
three months for those reporting pain was 4.6 (SD 2.1),
and severe pain was reported by 8.1 % of the subjects.
The most commonly reported pain areas were the lower
back (20.1 %) and neck (15.0 %) area (Table 3).
Associations between MSK pain and RLS
Univariable analysis per MSK pain region showed that
all pain regions, except for the upper back region and
the ‘other’ region, were significantly associated with RLS
(Table 3). The strongest associations were with pain re-
ported in the shoulder/arm region (odds ratio 6.2, 95 %
confidence interval 1.9–20.8) and pain reported in the
leg (3.9, 1.5–10.0). In multivariable logistic regression
analysis, BMI and smoking status were tested for con-
founding, but were not added to the regression models,
as they were not significantly associated with both MS
pain and RLS. Interaction between sex and MSK pain
variables was tested but did not prove to be significant.
Final regression models were adjusted for sex, DASS-21
scores and sleep quality and significant associations
between several MSK pain characteristics and RLS were
found (Table 4). RLS was associated with reporting long
duration of pain (3.6, 1.4–9.2), and medium (3.9, 1.2–12.7)
pain frequency in the last three months. In addition, RLS
tended to associate with mild (3.0, 1.0–8.2) and moderate
pain intensity (3.6, 1.1–12.3) during the last week. Lastly,
RLS was associated with both reporting one pain site (3.1,
1.1–8.5) and three or more pain sites (4.9, 1.6–14.6).
Discussion
This study demonstrated a significant association between
MSK pain and RLS in young adults from a community
cohort. Specifically, strong associations were found for
long duration of pain and a greater number of pain sites.
These associations remained present after adjusting for
sex, psychological distress and self-reported sleep quality.
MSK pain and RLS
The current study is, to our knowledge, the first on the as-
sociation between MSK pain and RLS in young adults.
Most previous studies on this topic have focused on female
populations and have often used chronic pain or rehabilita-
tion clinics to recruit their participants [15, 16, 26]. In
addition, these studies have focused on fibromyalgia, a
more specific subset of chronic widespread pain. Our study
includes both sexes, is among the first to sample from a
general population and involves a more general measure of
MSK pain. The questionnaires used covered multiple
aspects of MSK pain and therefore provide a thorough
assessment of different pain aspects. Lastly, adjustment
was made for important potential confounding factors.
The results of this study are consistent with the findings
by Stehlik et al. [17] in their study of Swedish middle-aged
women, where long duration of pain and a high number
of pain sites was strongly associated with RLS. A study in
Australian twin families by Champion [27] also showed
significant associations between two or more regional pain
sites and RLS. These findings are, together with the results
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Female 560 (53.8 %) 22 (68.8 %) 582 (54.3 %)
Male 480 (46.2 %) 10 (31.2 %) 490 (45.7 %)
Smoking 167 (16.1 %) 6 (18.8 %) 173 (16.2 %) 0.693
Mean Body Mass Index (kg/m2) (SD) 25.2 (5.5) 25.1 (4.4) 25.2 (5.5) 0.936
Sleep Quality 0.105 (0.023)
Very good 160 (15.7 %) 3 (9.7 %) 163 (15.5 %)
Fairly good 619 (60.6 %) 15 (48.4 %) 634 (60.3 %)
Fairly bad 217 (21.3 %) 11 (35.5 %) 228 (21.7 %)
Very bad 25 (2.4 %) 2 (6.5 %) 27 (2.6 %)
Mean DASS-21 scores (SD)
Depression Subscale 6.8 (8.2) 12.0 (11.5) 7.0 (8.4) 0.017
Anxiety Subscale 4.7 (5.7) 10.0 (8.0) 4.9 (5.8) 0.001
Stress Subscale 9.0 (8.1) 15.5 (11.0) 9.3 (8.3) 0.002
Total score 20.5 (19.5) 37.0 (28.3) 21.0 (20.0) 0.003
Any pain 380 (36.5 %) 21 (65.6 %) 401 (37.4 %) 0.001 (0.001)
Duration of pain 0.001 (<0.001)
No pain 660 (63.5 %) 11 (34.4 %) 671 (62.7 %)
Short duration 143 (13.8 %) 5 (15.6 %) 148 (13.8 %)
Long duration 236 (22.7 %) 16 (50.0 %) 252 (23.5 %)
Pain intensity last week 0.007 (0.001)
No pain 670 (64.7 %) 11 (35.5 %) 681 (63.8 %)
Mild pain 192 (18.5 %) 9 (29.0 %) 201 (18.8 %)
Moderate pain 118 (11.4 %) 8 (25.8 %) 126 (11.8 %)
Severe pain 56 (5.4 %) 3 (9.7 %) 59 (5.5 %)
Pain intensity last 3 months 0.016 (0.001)
No pain 682 (65.8 %) 13 (41.9 %) 695 (65.1 %)
Mild pain 169 (16.3 %) 6 (19.4 %) 175 (16.4 %)
Moderate pain 105 (10.1 %) 6 (19.4 %) 111 (10.4 %)
Severe pain 80 (7.7 %) 6 (19.4 %) 86 (8.1 %)
Pain frequency last 3 months 0.006 (0.001)
No pain 683 (65.9 %) 12 (38.7 %) 695 (65.1 %)
Low 164 (15.8 %) 6 (19.4 %) 170 (15.9 %)
Medium 84 (8.1 %) 6 (19.4 %) 90 (8.4 %)
High 105 (10.1 %) 7 (22.6 %) 112 (10.5 %)
Number of pain sites 0.005 (0.001)
No pain 660 (63.5 %) 11 (34.4 %) 671 (62.6 %)
One 165 (15.9 %) 8 (25.0 %) 173 (16.1 %)
Two 106 (10.2 %) 5 (15.6 %) 111 (10.4 %)
Three or more 109 (10.5 %) 8 (25.0 %) 117 (10.9 %)
aMean values with standard deviation provided for continuous data; numbers with percentages are provided for categorical data. Pearson’s Chi square test and
Chi square test for trend were used for comparisons of categorical data, independent samples t-tests for continuous data. Significant p-values are highlighted in
bold. DASS-21 Depression-, Anxiety and Stress Scale, RLS restless legs syndrome, SD standard deviation
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from our study, an extension to the earlier reported asso-
ciations between RLS and fibromyalgia [15, 16].
Psychological distress and sleep quality are important
factors in the relationship between pain and RLS. In
particular, pain in multiple body areas is often related to
depressive symptoms and other mental health problems
including anxiety disorders [28–30]. Depression is also
linked to altered pain thresholds and a predictor for future
pain [31]. Several studies have established strong associa-
tions between RLS and psychiatric comorbidity including
major depressive disorder and anxiety disorders [8, 32, 33].
Sleep disruption is a prominent complaint in RLS and is
also considered a risk factor for both panic disorder and
depression [10, 34]. High prevalence of sleep disruption
has been reported in chronic MSK pain [35] and experi-
mental studies in animals [36] and humans [37] have
shown that sleep disruption can induce musculoskeletal
sensitization and lower pain thresholds. In summary, the
relationship between pain and sleep can be considered
bidirectional [38], with an important mediating role for
emotional states. In our study, the associations between
RLS and MSK pain remained present even after adjusting
for psychological distress and sleep quality. This underlines
the probability of other shared mechanistic pathways in
these conditions, which will be discussed based on the
current literature.
The influence of heritable factors in RLS is supported by
family studies [39, 40] and genome-wide association studies
(GWAS) have identified at least six genetic loci in associ-
ation with RLS [41]. Observational studies suggest, at least
in part, a genetic basis in chronic pain syndromes including
chronic widespread pain and fibromyalgia and pain report-
ing behavior at multiple MSK pain sites as well [42–44]. In
GWAS a number of genes, involved in adrenergic and sero-
tonergic pathways, have been consistently linked to MSK
pain [45, 46]. Even though specific shared genes between
MSK pain and RLS have not been identified thus far, it is
evident that with genetic susceptibility being such an im-
portant component in the occurrence of both RLS and
MSK pain, shared genes (pleiotropy) might be an important
factor in the co-existence of these conditions.
The considerable role of dopamine dynamics in RLS is
illustrated by the efficacy of dopamine agonists in RLS
treatment [47] and supported by neuropathological studies
[48]. Combined with studies establishing the link between
brain iron deficiency and RLS [49, 50], it is hypothesized
that RLS might be seen primarily as an iron insufficiency
disorder, with resulting dopaminergic abnormalities [18].
Altered dopaminergic responses have been found in brain
imaging studies of fibromyalgia patients as well [51] and
reductions of dopamine metabolism have been found in
patients with depression [52]. Trials with dopamine agonist
pramipexole, frequently used in RLS treatment, have had
promising results in both fibromyalgia patients [53] and
patients with depression [54]. It is likely that alterations in
dopamine metabolism are an important factor to explain
the associations between RLS, MSK pain and depression.
In our study, RLS was not only strongly associated
with leg pain, significant associations were also found
for shoulder and arm pain, neck pain and lower back








Lower back 204 (19.6 %) 11 (34.4 %) 215 (20.1 %) 2.1 (1.0–4.3) 0.031
Neck 151 (14.5 %) 10 (31.3 %) 161 (15.0 %) 2.7 (1.1–6.3) 0.024
Upper back 93 (8.9 %) 6 (18.8 %) 99 (9.2 %) 2.4 (0.9–5.8) 0.066
Leg 82 (7.9 %) 8 (25.0 %) 90 (8.4 %) 3.9 (1.5–10.0) 0.005
Shoulder/arm 17 (1.6 %) 3 (9.4 %) 20 (1.9 %) 6.2 (1.9–20.8) 0.003
Other 62 (6.0 %) 1 (3.1 %) 63 (5.9 %) 0.5 (0.2–1.3) 0.169
aOdds ratios are given with bias-corrected bootstrapped 95 % confidence intervals. P-values of significant associations are highlighted in bold. RLS restless
legs syndrome
Table 2 Prevalence of restless legs related symptoms within the total cohort (n = 1072)
RLS symptoms assessed with 4 criteria Female Male Total
Urge to move the legs (at least 5 times/month) 158 (27.1 %) 142 (29.0 %) 300 (28.0 %)
Accompanied by dysaesthesia 57 (9.8 %) 31 (6.3 %) 88 (8.2 %)
Relieved by movement 95 (16.3 %) 70 (14.3 %) 165 (15.4 %)
Worsening at evening or night 104 (17.9 %) 51 (10.4 %) 155 (14.5 %)
RLS diagnosis (All 4 RLS criteria fulfilled) 22 (3.8 %) 10 (2.0 %) 32 (3.0 %)
RLS: Restless legs syndrome
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pain. An explanation for this finding might be found in
the concept of central sensitization of nociception. Central
sensitization is characterized by an increase in excitability
and synaptic efficacy of neurons in central nociceptive
pathways, manifests as pain hypersensitivity, and has been
implied as a causal or maintaining factor for pain in a wide
range of pathologies including osteoarthritis, temporo-
mandibular disorders, fibromyalgia, tension-type head-
ache, irritable bowel syndrome and low back pain [55, 56].
Recently, there has been evidence reported for central
sensitization in RLS. In an interesting study by Stiasny-
Kolster et al. [57] a three- to fourfold increase in sensitiv-
ity for pinprick stimuli in untreated RLS-patients was
found, along with a reduced tactile sensitivity and para-
doxical heat sensation. Treatment with L-Dopa reversed
or reduced these symptoms, prompting the authors to
conclude that sensory symptoms in RLS are possibly
explained by impaired dopaminergic control on spinal
nociceptive neurons and central dis-inhibition. The pres-
ence of central sensitization or dis-inhibition in RLS
sufferers might account for the high comorbidity of mul-
tiple site MSK pain.
In summary, we think genetic factors might account
for a large part of dysregulation in dopaminergic metab-
olism, involved in the onset of RLS and MSK pain, but
also depression. In turn, the sleep disruption caused by
RLS results in lowering of pain thresholds and an increase
of depressive symptoms, both related to an increased risk
of future pain. The intimate relationship between these
conditions requires the clinician to have special attention
for comorbid occurrence.
Limitations
Although we acknowledge the modest response rates
(51.4 %) in our study, one needs to bear in mind that the
data used for this study were part of an extensive cohort
Table 4 Odds ratios for RLS diagnosis with musculoskeletal pain variables as the input variablea
Unadjusted Adjusted for sex Adjusted for sex and DASS-21 Adjusted for sex, DASS-21 and sleep quality
Any body pain n = 1072 n = 1072 n = 1047 n = 1030
No REF REF REF REF
Yes 3.3 (1.5–7.2)** 3.1 (1.5–6.7)** 2.8 (1.2–6.6)* 3.0 (1.3–7.1)*
Pain duration n = 1071 n = 1071 n = 1046 n = 1029
No pain REF REF REF REF
Short duration 2.1 (0.6–7.4) 2.0 (0.6–7.1) 1.9 (0.6–6.4) 2.2 (0.6–7.7)
Long duration 4.1 (1.8–9.3)** 3.8 (1.7–8.6)** 3.3 (1.4–7.5)** 3.6 (1.4–9.2)**
Pain intensity last week n = 1067 n = 1067 n = 1044 n = 1027
No pain REF REF REF REF
Mild pain 2.9 (1.1–7.4)* 2.7 (1.1–7.0)* 2.7 (1.0–7.0)* 3.0 (1.0–8.2)*
Moderate pain 4.1 (1.6–10.7)** 4.0 (1.6–10.2)** 3.3 (1.1–10.1)* 3.6 (1.1–12.3)*
Severe pain 3.3 (0.9–12.1) 2.8 (0.8–10.4) 2.7 (0.8–9.4) 2.9 (0.8–10.0)
Pain intensity last 3 months n = 1067 n = 1067 n = 1044 n = 1027
No pain REF REF REF REF
Mild pain 1.9 (0.6–5.6) 1.8 (0.6–5.4) 1.6 (0.6–5.0) 1.8 (0.6–5.4)
Moderate pain 3.0 (0.9–9.9) 2.9 (0.9–9.3) 2.5 (0.9–7.4) 2.8 (0.8–10.0)
Severe pain 3.9 (1.3–11.5)* 3.5 (1.2–10.3)* 3.0 (1.0–8.6)* 3.2 (0.9–10.6)
Pain frequency last 3 months n = 1067 n = 1067 n = 1044 n = 1027
No pain REF REF REF REF
Low 2.1 (0.7–5.8) 2.0 (0.7–5.7) 1.9 (0.7–5.4) 2.1 (0.7–6.5)
Moderate 4.1 (1.3–13.1)* 3.8 (1.2–12.2)* 3.5 (1.2–10.4)* 3.9 (1.2–12.7)*
High 3.8 (1.4–10.4)** 3.4 (1.3–9.4)* 2.9 (1.0–8.8) 3.2 (1.0–10.4)
Number of pain sites n = 1072 n = 1072 n = 1047 n = 1030
No pain REF REF REF REF
One site 2.9 (1.2–7.3)* 2.8 (1.1–7.1)* 2.8 (0.9–8.4) 3.1 (1.1–8.5)*
Two sites 3.1 (0.9–10.0) 2.9 (0.9–9.1) 2.4 (0.7–7.8) 2.6 (0.8–8.9)
Three or more 6.1 (2.0–18.5)** 5.5 (1.8–16.9)** 4.5 (1.4–15.3)* 4.9 (1.6–14.6)**
aOdds ratios are given with 95 % Confidence Intervals. The DASS-21 total score showed strong correlation with the three subscales and was used as a continuous
covariate in the multivariable logistic regression analysis. * = p <0.05; ** = p <0.01. RLS restless legs syndrome, DASS-21 Depression-, Anxiety and Stress Scale
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study, involving questionnaires, physical assessments and
for most participants also an overnight sleep study [20]. In
our experience, young adults were a particularly challen-
ging group to recruit for this study. Further, as the sample
remains representative of the broader Western Australian
population of similarly aged young adults, we are
confident the associations found are likely to be true for
the population. The RLS-categorization was based on self-
reported measures, which might increase prevalence
estimates compared to a clinician-based diagnosis. We
used the IRLSSG [1] screening questions in conjunction
with frequency of experiencing symptoms at least 5 times
per month as conservative criteria for diagnosis of RLS.
Alternate questionnaires for RLS diagnosis, such as the
Cambridge-Hopkins questionnaire [58], have been sug-
gested as an alternative to the 4 screening questions based
on their ability to better differentiate disorders that could
mimic RLS [59]. However in the large epidemiological
Raine Study where participants provided extensive ques-
tionnaire datasets, the 4 screening questions were deemed
sufficient to make the RLS diagnosis while minimising
participant burden. Also the likelihood of common RLS
mimics being present in the younger cohort, including
conditions as neuropathy, radiculopathy and arthritic
pains [59], was deemed low. Despite these potential limita-
tions we still found strong, consistent associations. Even
though we did not find a statistically significant difference,
the RLS prevalence was almost twice as high in females as
in males in our samples, consistent with previous reports
[2, 3, 5]. The 95 % confidence interval for the difference in
RLS-prevalence between males and females from our
sample was 0 to 3.7 %, in keeping with the known female
predominance. Also, the overall prevalence of RLS found
in this study is congruent with other large epidemiological
surveys [2–6] supporting the representativeness of the
Raine cohort and the conservative criteria used for RLS
diagnosis. Most known confounders, based on previous
literature, were controlled for, but we cannot be certain
that all potential confounders were measured. Because of
the relatively small group that satisfied the RLS criteria,
confidence intervals in our risk estimations were wide.
Larger studies are needed if a more accurate estimation of
RLS-prevalence risk in MSK pain is sought. Lastly, while
we found strong associations between RLS and MSK pain,
the cross-sectional nature of our study limits the possi-
bility to make statements on causality. Future studies,
particularly prospective studies, are needed to effectively
address this causality question.
Clinical implications
We have found strong independent associations between
MSK pain and RLS in young adults. This finding indicates
that there may be an opportunity for early intervention
and prompt clinicians to screen for RLS in young adults
with MSK pain, and vice versa. Each condition should be
regarded in the light of the other. Consideration of the co-
morbidity of MSK pain and RLS, as well as addressing
psychological symptoms such as depression, may be par-
ticularly important in determining management needs. In
subjects showing an overlap between RLS, multiple pains
and depressive symptoms, dopamine agonists such as pra-
mipexole might prove especially effective, as already has
been shown for these conditions separately [47, 53, 54].
While pharmalogical treatment is the frontline approach
for RLS [47], in RLS sufferers with comorbid MSK pain
non-pharmalogical strategies such as exercise programs
[60] might be a useful adjunct. Intervention studies are
needed to further investigate treatment options in this
particular category of patients.
Conclusions
In conclusion, our study demonstrates associations of RLS
with long duration of MSK pain and a high number of pain
sites in a community-based setting in young adults. The
underlying shared mechanisms might be related to sleep
disruption, psychological distress, genetic factors, dopa-
minergic dysfunction or central sensitization. Additional
research is needed to clarify the mechanisms behind these
associations and to improve treatment options in patients
suffering simultaneously from these two conditions.
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